丁苯酞软胶囊联合依达拉奉用于临床治疗脑梗死的疗效分析

Efficacy Analysis of Butylphthalide Soft Capsule Combined with Edaravone in Clinical Treatment of Cerebral Infarction

目的探析脑梗死患者接受丁苯酞软胶囊联合依达拉奉治疗的临床疗效。方法方便选取该院2018年1月-2021年4月接收的85例脑梗死患者为观察对象,结合患者入院顺序,按单双号将患者分成两组,接受依达拉奉单独治疗43例单号患者入选对照组,接受丁苯酞软胶囊联合依达拉奉治疗的42例双号患者入选观察组,比较美国国立卫生院神经功能缺损评分(NIHSS)评分与Bl指数、疗效、不良反应及炎症因子变化。结果治疗后观察组总有效率为88.10%,优于对照组,差异有统计学意义(χ^(2)=4.276,P<0.05);对比治疗后NIHSS评分与Barthel指数,观察组数值分别为(4.79±1.33)分、(47.78±2.29)分,优于对照组,差异有统计学意义(P<0.05);观察组治疗后不良反应发生率为11.90%,少于对照组,差异有统计学意义(P<0.05);观察组白细胞介素-8(IL-8)(13.42±2.52)pg/mL、白细胞介素-10(IL-10)(8.48±1.09)pg/mL、C-反应蛋白(CRP)(6.46±2.14)mg/L低于对照组,差异有统计学意义(P<0.05)。结论脑梗死患者接受丁苯酞软胶囊联合依达拉奉治疗,对患者病情、炎症因子改善作用明显,有助于提升患者神经功能与日常生活能力,相比于依达拉奉单独治疗,更具安全性。

Objective To explore the clinical efficacy of butylphthalide soft capsule combined with edaravone in patients with cerebral infarction.Methods Conveniently selected 85 cases of cerebral infarction patients received in the hospital from January 2018 to April 2021 were taken as observation objects,combined with the order of admission,the patients were divided into two groups according to odd and even numbers,and 43 cases of single number were treated by edaravone alone.The patients were selected as the control group.42 double-number patients who received butylphthalide soft capsule combined with edaravone were selected as the observation group.Comparison of the National Institutes of Health Neurological Impairment Score(NIHSS)score and Bl index,efficacy,adverse reactions and changes in inflammatory factors.Results After treatment,the total effective rate of the observation group was 88.10%,which was better than that of the control group.The difference was statistically significant(χ^(2)=4.276,P<0.05);after treatment,the NIHSS score and Barthel index were compared,and the observation group values were(4.79±1.33)points,(47.78±2.29)points,which was better than the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions after treatment in the observation group was 11.90%,which was less than that in the control group,and the difference was statistically significant(P<0.05);the observation group interleukin-8(IL-8)(13.42±2.52)pg/mL,Interleukin-10(IL-10)(8.48±1.09)pg/mL,C-reactive protein(CRP)(6.46±2.14)mg/L were lower than the control group,the difference was statistically significant(P<0.05).Conclusion Patients with cerebral infarction receiving butylphthalide soft capsules combined with edaravone can significantly improve the patient’s condition and inflammatory factors,and help improve the patients’neurological function and ability of daily living.Compared with edaravone alone,it is safer.